Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“First global Phase 3 trial to show a substantial survival advantage over chemo in 2L SCLC!
Tarlatamab significantly improves OS after progression on platinum-based chemo.
More posts featuring SCLC.